Abstract Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with diabetes mellitus. Moreover, rates of CVD mortality are two to four times higher in diabetes than in those without diabetes. It was conventional thinking that achieving near-normoglycemia would help reduce CVD risk and overall mortality in type 2 diabetes mellitus. Several recent large trials attempted to answer this question using a randomized control trial design with a conventional therapy and an intensive control arm. Surprisingly, these trials did not demonstrate neither mortality nor a CVD advantage with intensive glycemic control. Moreover, some studies (e.g., the ACCORD [Action to Control Cardiovascular Risk in Diabetes] study) showed increased mortality in the intensive control arm. In this review, our goal is to summarize the findings of the major trials in this field and to explore the potential reasons for why these trials had largely negative results. We conclude with some lessons that may be applied to the clinical management of patients with diabetes.
Introduction
Cardiovascular disease (CVD) remains the single greatest cause of morbidity and mortality for patients with type 2 diabetes mellitus (T2DM) [1] . Ever since the UGDP (University Group Diabetes Program) study in the 1960s [2] , defining the role of glucose control in modulating CVD risk has been akin to the "holy grail" in the field of clinical diabetes. The reports of several recent large and "definitive" clinical trials have generated more controversy (and scores of publications), largely because these trials failed to confirm what many in the field already believed-that achieving near-normoglycemia would provide clear benefits in reducing CVD events and mortality. This was not unreasonable, given the microvascular benefits demonstrated in the UKPDS (United Kingdom Prospective Diabetes Study) and the unequivocal cardiovascular results in type 1 diabetes mellitus (T1DM) in DCCT/EDIC (Diabetes Interventions and Complications/Epidemiology of Diabetes Interventions and Complications) [3, 4] . The unexpected findings of the more recent trials provide an opportunity to revisit existing assumptions and the approach to patients at risk. We provide a brief review of the relevant trials and discussion of how and what should be applied to current standards of clinical care in T2DM.
Hyperglycemia and Cardiovascular Risk
Overall mortality in T2DM has decreased significantly [5] over the years, presumably due to intense risk factor modification, but T2DM is still the 7th leading cause of death in the United States [1] and rates of mortality and cardiovascular events remain unacceptably high. The overall death rate in T2DM is twice as high and CVD death rate is two to four times as high as those without T2DM [1] . In population-based studies, including diabetic and nondiabetic cohorts, hemoglobin A 1c (HbA 1c ) has been reported as an independent predictor of all-cause and CVD mortality [6] [7] [8] . Among individuals with diabetes, every 1% rise in HbA 1c is associated with a 30% increase in all-cause mortality and a 40% increase in CVD mortality [9] . In the Atherosclerosis Risk in Communities study, higher HbA 1c in community-dwelling, nondiabetic adults was also associated with higher risk of CVD and death [10] .
Clinical Trials of Glycemic Control in Prevention of Cardiovascular Disease
Below is a brief description of the major trials designed to test the role of intensive glycemic control and CVD risk in T2DM. Although these trials share a central hypothesis and treatment strategy (intensive vs conventional treatment), they differ in terms of patient characteristics and baseline CVD risk. Relevant details of the studies, including CVD risk factors (at baseline and at study end) and a summary of study outcomes, are shown in Table 1 .
UGDP
This early trial, conducted in the 1960s, was the first to directly address the role of glucose control in preventing diabetic complications. Patients with recently diagnosed T2DM were assigned to a standard, fixed low-dose insulin regimen, a more "intensive" treatment using variable insulin dosing (designed to achieve fasting glucose < 110 mg/dL, and less than 210 mg/dL following oral glucose challenge), or treatment with a sulfonylurea (SU), a biguanide (phenformin), or placebo. The unexpected findings of increased CVD mortality in the SU-treated patients generated a landslide of controversy, which has persisted for decades. It is also of note that CVD mortality was similar in both insulin groups and placebo, despite the lower glucose levels achieved in the variable insulin-treated group [2] .
UKPDS
The UKPDS was the first of the recent large-scale multicenter trials designed to investigate the role of glycemic control in macrovascular and microvascular complications of T2DM. Over 4000 participants with newly diagnosed diabetes were recruited and followed for 10 years after randomization to an intensified regimen (based on SU or insulin), or to conventional therapy (based on diet management). Despite achieving a significant difference in glycemic control (median HbA 1c 7.0% vs 7.9% in the intensive and conventional groups, respectively), primary analysis failed to show a statistically significant risk reduction for myocardial infarction (MI). The occurrence of any diabetes-related end point was reduced, primarily due to a 25% risk reduction in microvascular end points [11] . In contrast, in a subset of the UKPDS, 753 overweight individuals randomly assigned to metformin versus conventional management did show a clinical benefit of intensive glucose control, with risk reductions of 42% for diabetes-related death, 39% for fatal/nonfatal MI, and 36% for all-cause mortality [12] . At study completion, patients were returned to their usual source of medical care. Baseline differences in HbA 1c were lost by 1 year, and after 5 years, there were no significant differences in HbA 1c (7.8%), body weight, lipid levels, or blood pressure among the groups. Despite this, reductions in the relative risk of diabetes-related end points were maintained 10 years after completion of the intervention trial, and now included a 15% reduction in MI and a 13% reduction in all-cause mortality in the main (UKPDS 33) trial [13] .
ACCORD
In the ACCORD trial, over 10,000 patients with established T2DM and at high risk for CVD were randomly assigned to an intensive treatment group (HbA 1c goal<6%) or to a standard treatment group (HbA 1c goal 7% to 7.9%). Treatment was guided by an algorithm employing multiple antidiabetic drugs (including oral medications and insulin) in both arms. Both treatment groups achieved a stable HbA 1c level (6.4% and 7.5%, in the intensive and standard groups, respectively) within 1 year of randomization. After a mean follow-up of 3.5 years, the study was halted due to the unexpected finding of increased all-cause mortality in the intensive therapy group. In contrast to the increase in mortality, there was a nonsignificant trend toward a reduction in the primary outcome (a composite of nonfatal MI, nonfatal stroke, or cardiovascular death) within the intensive group, mainly due to a reduction in nonfatal MI [14] .
ADVANCE
The ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial assessed the effects of intensive glycemic therapy on major vascular outcomes in patients with established T2DM and high risk for CVD [15] . Over 11,000 patients were randomized to an intensive glucose-control strategy using an SU (gliclazide) and additional medications as required to achieve the target HbA 1c level (≤ 6.5%) versus a standard treatment group. The primary end point was a composite of major macrovascular events (death from CVD causes, nonfatal MI, or nonfatal stroke) and major microvascular events (new or worsening nephropathy or retinopathy). After a median follow-up of 5 years, the mean HbA 1c level was lower in the intensive control group (6.5%) compared to the standard control group (7.3%). Compared with standard therapy, intensive therapy was associated with a decrease in the incidence of the primary end point (hazard ratio [HR] 0.90, 95% CI 0.82-0.98, P00.01), primarily due to a reduction in microvascular outcomes (HR 0.86, 95% CI 0.77-0.97, P00.01). Intensive therapy had no significant effect on the incidence of macrovascular events (HR 0.94, 95% CI 0.84-1.06, P00.32), or allcause or CVD mortality.
VADT
The VADT (Veterans Affairs Diabetes Trial) was a multicenter trial designed to assess cardiovascular outcomes in response to intensive versus standard glucose-lowering therapy in 1791 patients with long-standing T2DM and suboptimal glycemic control. A variety of glucose-lowering medications were used to achieve a goal of 1.5% reduction in HbA 1c beyond that achieved by standard therapy. The primary outcome of the study was the time from randomization to the first occurrence of a major cardiovascular event (a composite of MI, stroke, death from cardiovascular causes, congestive heart failure, surgery for vascular disease, inoperable coronary disease, and amputation for ischemic gangrene). Although significant glycemic separation was achieved (mean HbA 1c 6.9% vs 8.4%,) after a mean follow-up of 5.6 years, the primary outcome (as well as individual components) was not significantly lower in the intensive therapy arm versus the standard therapy arm (HR 0.88, 95% CI 0.74-1.05, P00.12). Compared to conventional therapy, there was no difference between groups in death from CVD causes (HR 1.32, 95% CI 0.81-2.14) or death from any cause (HR 1.07, 95% CI 0.81-1.42) [16] .
Meta-Analyses of Major Trials
Despite the largely negative results in the individual trials described above, two recent systematic reviews that combined the results from several studies concluded that intensive management may, in fact, reduce the risk of coronary events in T2DM. In a meta-analysis performed by Ray et al., which included data from the UKPDS, ACCORD, ADVANCE, VADT and PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events) studies [17] , intensive glycemic control resulted in a 17% reduction in nonfatal MI and 15% reduction in coronary heart disease events [18•] . Importantly, there was no significant heterogeneity of this result across the studies, which differed with respect to baseline subject characteristics and drug regimen employed. Intensive management had no significant effect on stroke or all-cause mortality in this study. A separate analysis of the same trials (excluding PROactive) demonstrated a similar 16% risk reduction for nonfatal MI and no effect on cardiovascular or allcause mortality [19•] . A larger group of studies (including the UGDP and PROactive) was subjected to meta-analysis by Boussageon et al., but resulted in similar conclusions [20•] .
Why Did Recent Trials Fail to Demonstrate the Expected CVD Benefit of Intensive Glucose Control?
Taken as a whole, these recent studies suggest that intensive glycemic control in T2DM plays, at best, a modest role in CVD prevention and may in fact be harmful. Here, we consider some possible scenarios that may explain these unexpected results:
Glycemic Control Does Not Directly Modulate CVD Risk/Events in T2DM Despite the strong epidemiological evidence of the association between T2DM and CVD, it may be that glycemia per se is not the key metabolic factor in its pathogenesis [21] . In contrast to T1DM (for which there is clear evidence of the benefit of intensive glucose control on CVD [4] ), T2DM is a more complex metabolic disorder characterized by dyslipidemia, insulin resistance, and obesity-all of which are directly implicated in atherothrombosis. In support of this is the observation that increased CVD risk exists in prediabetic states: dyslipidemia, hypertension, insulin resistance, and obesity often precede overt hyperglycemia [22, 23] , although in some studies, progression to overt diabetes does seem to further increase CVD risk [24] . Of note, it has been difficult to separate effects of hyperglycemia from hyperlipidemia in experimental models and there is controversy whether "pure" hyperglycemia is atherogenic, at least in animals [25] .
The lipid-centric view of atherogenesis proposes that dyslipidemia is the primary pathogenetic factor responsible for accelerated atherosclerosis in patients with diabetes [26] . The characteristic diabetic dyslipidemia-low high-density lipoprotein cholesterol, elevated triglycerides, and small, dense low-density lipoprotein particles-has been associated with accelerated atherosclerosis in epidemiologic studies. The fact that treatment of hyperlipidemia has consistently (and relatively robustly) been shown to reduce CVD events in patients with diabetes supports this view [27] [28] [29] . Further, multiple risk factor intervention, as in the Steno trial, which targeted reductions in blood pressure and lipids, antiplatelet therapy, and smoking cessation in addition to glucose control, resulted in a dramatic 57% reduction in CVD mortality after 13 years of follow-up [30] . The intensive treatment group in this study had a glycemic target of less than 6.5%, and achieved HbA 1c of 7.9% at the end of active intervention, compared to 9.0% in the conventional therapy group, although the independent contribution of glycemic control could not be determined in this study.
Glycemic Control Does Modulate CVD, but Issues Related to Study Design and Specific Drug Regimens Have Obscured This Relationship

Drug Toxicity
Certain antidiabetic drugs or combinations of drugs used in recent trials may themselves have adverse cardiovascular effects, which could have obscured the actual benefits of improved glycemic control. It also should be noted that these trials relied virtually exclusively on pharmacologic interventions and did not include any serious effort at lifestyle change (weight loss, increased physical activity), which might be expected to have cardiovascular benefits.
Rosiglitazone. Since the publication of the first Nissen report in 2007 [31] , evidence has been mounting that rosiglitazone is associated with increased CVD risk and use of this agent is now limited. A recent meta-analysis of 56 trials published over 11 years found that rosiglitazone use was associated with increased risk of MI, (odds ratio 1.28, 95% CI 1.02-1.61, P00.04), although not cardiovascular mortality [32•] . In the ACCORD trial, 92% of subjects in the intensive arm were being treated with rosiglitazone at the end of the study, compared with 58% subjects in the standard therapy group. While preliminary analysis could not attribute the excess mortality risk in the intensive treatment group to the use of any particular agent, more detailed analysis is ongoing [33] . In the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetics) trial, an open-label study designed (and powered) to examine the CVD effects of rosiglitazone, there was no increased risk for CVD death, MI, or stroke in subjects randomized to rosiglitazone when compared to non-thiazolidinedione (TZD) treatment regimens, although heart failure risk was increased [34] . Rosiglitazone was also used extensively in the BARI 2D (Bypass Angioplasty Revascularization Investigation-Type 2 Diabetes) study, which compared early revascularization versus intensive medical management in patients with stable coronary artery disease. Among subjects assigned to a strategy of insulin sensitization, 55% received rosiglitazone (often in combination with metformin) and no differences in survival or major CVD events were apparent after 5 years of follow-up [35] . Use of TZDs (including rosiglitazone) in VADT was common in both treatment groups (53% for intensive vs 42% for standard therapy). TZDs were not used in UKPDS and used infrequently in ADVANCE (17 and 11% in the intensive and standard groups, respectively).
Sulfonylureas. The UGDP was the first study to raise the possibility that use of a SU (in this case, tolbutamide) was associated with higher mortality compared to with insulin or diet [2] . Subsequently, several studies also provided evidence that SU use may be associated with increased CVD risk [36, 37] . Furthermore, a greater risk of death has been reported with increased use of higher doses of first-generation SUs, suggesting a dose-dependent effect [38] . The proposed mechanism for SU cardiac toxicity is related to the effect of KATP channel inhibition on myocardial ischemic preconditioning, but the clinical relevance of this remains to be proven. It is also unclear whether newer SUs have a better safety profile [39] . SU use was more common in the intensive treatment arms of ACCORD (78% vs 68%), ADVANCE (93% vs 59%), and VADT (57% vs 42%) compared to the standard treatment groups. However, the UKPDS, which was designed (and powered) to address the question of SU cardiotoxicity, reported no difference in MI or diabetes-related death between SU, insulin, and conventional treatment groups [11] .
Insulin. Since insulin resistance (and the accompanying hyperinsulinemia) is associated with increased CVD risk, questions have been raised about the role of insulin therapy in promoting CVD. Insulin's opposing vascular actions as a vasodilator (via enhanced synthesis of nitric oxide) and also a mitogen and vasoconstrictor (via increased production of endothelin) suggest it plays a complex role in vascular health [40] . Signaling via the phosphatidylinositol 3-kinase pathway, which regulates endothelial nitric oxide synthase activity, is impaired in insulin-resistant states, but activity in the mitogen-activated protein kinase system is not, and in the setting of hyperinsulinemia, may be increased. This tends to shift the balance to favor insulin's proatherosclerotic effects, including cell proliferation and vasoconstriction. Presumably, in the setting of insulin resistance, the high levels of exogenous insulin required to achieve glycemic control could have similar proatherosclerotic effects. Further, the weight gain that often accompanies intensive insulin therapy may itself contribute to increased CVD risk.
Results from epidemiological studies suggest that insulin treatment is associated with increased CVD risk. For example, the Euro Heart Survey registry study reported that insulin treatment was associated with an adjusted HR of 2.23 for mortality (95% CI 1.24-4.03) and 1.27 for all CVD events (95% CI 0.85-1.87), compared to treatment with oral hypoglycemic drugs [41] . However, observational studies are confounded because insulin use may simply be a proxy for more severe diabetes. Patients with longer duration of diabetes and greater insulin resistance are more likely to be treated with insulin and also to have coexisting CVD, making it difficult to assign causality. Insulin treatment was more common in the intensive treatment arms of ACCORD (77% vs 55%), AD-VANCE (41% vs 24%), and VADT (89% vs 74%). Unfortunately, no analysis has been reported of insulin doses in relationship to CVD outcomes in these studies.
Hypoglycemia
Iatrogenic hypoglycemia is a well-recognized consequence of intensive glucose management, particularly when insulinbased regimens are used. Hypoglycemic episodes induce sympathetic nervous system activation and can result in arrhythmia, myocardial ischemia, and sudden death [42] [43] [44] and may be particularly dangerous in the presence of cardiac autonomic neuropathy [45] . In all the recent trials, intensive treatment was associated with significantly increased rates of hypoglycemia, including severe episodes (defined as requiring assistance of another person). In ACCORD, 15.9% of participants in the intensive treatment group experienced at least one episode of hypoglycemia requiring any assistance, compared with 5.0% in the conventional treatment group, and 10.3% versus 3.4% had hypoglycemia requiring medical intervention [14] . Detailed analysis by the ACCORD research group confirmed that the occurrence of severe hypoglycemia was associated with increased mortality risk in both treatment arms and may have contributed to 5% to 6% of deaths during the trial. However, of the 74 participants who reported an episode of severe hypoglycemia and subsequently died, only 6 of these deaths occurred within 30 days of the hypoglycemic event and the investigators concluded that hypoglycemia did not explain the increased mortality seen in the intensive treatment group [46] . Further, in a post hoc analysis, higher (not lower) mean on-treatment HbA 1c was a significant predictor of mortality, an effect that appeared to be greater in the intensive treatment group [47] .
Severe hypoglycemia was also relatively frequent in the VADT study and was a powerful predictor of cardiovascular death (HR 4.04, P00.02) [48] . A recent analysis from the ADVANCE trial also showed an association between severe hypoglycemia and adverse study outcomes in both treatment groups, including cardiovascular and noncardiovascular outcomes and all-cause mortality [49] . Adverse CVD outcomes or death occurred 1.05-1.56 years after the most recently reported severe hypoglycemic episode. These finding support the view, also proposed by others [50] , that the occurrence of severe hypoglycemia is a marker of patient vulnerability and may not be causally related to CVD and mortality outcomes. However, in all of the trials, plasma glucose level at the time of death was generally not known. Further, the presence of hypoglycemia unawareness (which may occur as a consequence of frequent hypoglycemia) may also tend to obscure the temporal relationship between severe hypoglycemic events and adverse outcomes. Interestingly, a recent analysis from ACCORD demonstrated an unexpected inverse relationship between the frequency of minor hypoglycemic episodes (defined as self-monitored blood glucose < 70 mg/dL or "minor but uncomfortable" hypoglycemia symptoms) and mortality risk in the intensive treatment group. The possible blunting of counterregulatory responses (including increases in catecholamines) in the setting of frequent hypoglycemia was offered as a possible explanation [51•].
Other Study Design Issues Inadequate Power. As mentioned above, as compared to the period of 1950-1975, all-cause and cardiovascular mortality declined in individuals with and without diabetes in the period of 1976-2001 [5] . Thus, event rates in many of the recent large trials were lower than anticipated, and consistent with national trends and multiple risk factors targeting in current T2DM treatment. In the ACCORD study, the rate of all-cause mortality was 14.3 and 11.3 per 1000 patientyears in the intensive and conventional arms, respectivelyapproximately half of what was predicted. This suggests the study was underpowered to detect treatment group differences, especially given the relatively short follow-up period of 3.5 years. In VADT, ADVANCE, and UKPDS the event rates were somewhat higher than in ACCORD, varying between 18.2 and 20.6 per 1000 patient-years in the various arms of the studies, but still may have been inadequate to detect treatment group differences. Further, the average duration of follow-up in ACCORD, ADVANCE, and VADT (3.5, 5, and 5.6 years, respectively) was relatively short. In fact, the premature termination of ACCORD may have precluded the emergence of a statistically significant effect of intensive treatment in reducing the primary outcome, which showed an HR of 0.90 (95% CI 0.78-1.04) at the time the trial was stopped. In contrast, the EDIC and UKPDS demonstrated a reduction in CVD outcomes with average total follow-up periods of 16-18 years. Taken together, it appears that larger and longer-duration studies may be required to detect a benefit of intensive glycemic control on mortality and CVD outcomes. Nonetheless, current evidence supports the conclusion that any benefit of intensive management on CVD outcomes is likely to be modest.
Too Rapid Correction of Hyperglycemia. It has also been proposed that a too rapid rate of glycemia reduction could be a factor in adverse CVD outcomes. Temporary worsening of diabetic retinopathy following initiation of intensive glucose control is well recognized and is usually attributed to a reduction of retinal blood flow, resulting in capillary closure or retinal microhemorrhages [52, 53] . In a similar fashion, acute reduction of hyperglycemia could result in adverse hemodynamic changes that precipitate cardiac events, although this has not been established. In ACCORD, subjects in the intensive arm experienced a rapid decline in HbA 1c (8% to~6.7% in the first year), although cardiovascular event rates were highest in years 2 to 7 [47] .
Selection of the Wrong Glucose Target. Postprandial (after a meal) or postchallenge (after an oral glucose challenge) hyperglycemia has been strongly associated with CVD risk in observational studies and may be a better predictor of mortality than is fasting hyperglycemia [54, 55] . Moreover, postchallenge hyperglycemia tends to correlate strongly with CVD markers and subclinical atherosclerosis [56, 57] . However, in most clinical trials, lower HbA 1c (and in some cases, lower fasting glucose) was the glycemic target and no specific effort was made to reduce postprandial hyperglycemia. Interestingly, in the STOP-NIDDM (Study to Prevent Non-InsulinDependent Diabetes Mellitus) trial, conducted in a prediabetic population with impaired glucose tolerance, treatment with the drug acarbose, which blunts postprandial glucose elevations, there was a 49% reduction in CVD end points compared with placebo [58] . However, in a similar population, treatment with another prandial glucose regulator, nateglinide, failed to show cardiovascular benefits [59] .
Glycemic variability per se has been proposed to have a unique and underappreciated role in the pathogenesis of diabetic vascular complications [60, 61] , potentially via induction of oxidative stress. In an animal model, oscillating glucose levels appear to accelerate atherosclerotic processes, including monocyte adhesion, more than constant levels of hyperglycemia [62] . However, glycemic variability is difficult to quantify in clinical situations [ Although the role of glycemic control in the prevention of microvascular complications has been firmly established, it is also known that glucose control contributes much less to the progression of established complications. A similar paradigm may be at play with macrovascular disease-that aggressive glucose lowering in the setting of established atherosclerosis may be ineffective, or even harmful. Evidence from recent trials tends to support this hypothesis. However, since subclinical atherosclerosis probably exists in a substantial proportion of patients with T2DM but was not directly assessed in these studies, misclassification of subjects confounds efforts to confirm this. Nonetheless, duration of diabetes can be viewed as a proxy for atherosclerotic burden, in that patients with long-standing diabetes probably have more subclinical (as well as clinical) CVD.
Participants enrolled in UKPDS, which demonstrated reduced risk of MI and all-cause mortality after about 16 years follow-up, were relatively young (mean age 53 years) with known diabetes duration of less than 1 year. In contrast, ADVANCE, ACCORD, and VADT recruited participants who were older (mean ages 60-66 years, with an average duration of diabetes ranging from 7.9-11.5 years at baseline)-and failed to demonstrate significant cardiovascular benefit of intensive management. Subgroup analysis from ACCORD suggested that patients without a previous cardiovascular event and those with lower baseline HbA 1c did show benefit from intensive glucose management [14, 64] .
In a post hoc analysis of the VADT study, intensive treatment resulted in a 26% reduction in cardiovascular events if initiated within 15 years of diabetes diagnosis (P00.006), but was less beneficial and possibly harmful for subjects with longer-duration diabetes [65•] . In a VADT substudy, subjects with lower coronary artery calcium scores (reflecting less atherosclerotic burden) showed benefit from intensive treatment, whereas those with higher scores (> 100) did not [66] . In the ADVANCE study, the risk reduction for the combined major vascular outcome was greater for patients without known macrovascular disease at baseline (−14% vs −4%) [15, 46] . Further, in a meta-analysis of the four major trials, subjects with shorter duration of diabetes (< 5 years) and those without a prior history of micro-or macrovascular disease showed significant reduction in major CVD events with intensive therapy [67] . Additional evidence in support of the benefits of earlier initiation of intensive management comes from the DCCT/EDIC study in T1DM, in which the average age at randomization was 27 years, and a 57% reduction in major cardiovascular outcomes was observed [4] .
From these studies, one could reasonably conclude that intensive glycemic control may be more effective in patients with earlier diabetes and less extensive atherosclerosis, although the mechanisms for this differential effect are not clear. It may be that metabolic factors (e.g., hyperglycemia) demonstrated to play a role in the development of atherosclerosis are less able to modulate the inflammatory process once it is well established. It has been proposed that glucose reduction in patients with established atherosclerosis may disrupt previously stable plaques and result in increased plaque rupture and clinical coronary events [68] . Further, hyperglycemia-induced tissue damage, including formation of advanced glycation end products, may not be readily reversible by restoration of normoglycemia and may contribute to the "legacy effect" (also called "metabolic memory"). The concept of glycemic legacy refers to the observation that the benefits of early glycemic control appear to persist for many years after glucose control reverts to that of a standard treatment control group, as in the DCCT/EDIC study [4, 69] . Viewed another way, a "bad glycemic legacy" from many years of poor glucose control may be what drives the risk of diabetes vascular complications and cannot be reversed by a relatively brief period (3-5 years) of improved glucose control [70] .
Conclusions
Now that the dust has settled, it seems that intensive glucose control provides, at best, a modest benefit in preventing CVD events and mortality in selected patients. Much has already been written about the inconclusive and otherwise disappointing results of recent trials and how the information from these studies should be applied to clinical care of patients with T2DM. Selection of specific glycemic targets and drug regimens remains problematic. However, there are reasonable conclusions that can be drawn from the available results:
1. Aggressive multidrug and high-dose insulin regimens should probably be avoided in older T2DM patients and those with established CVD, although evidence suggests that strict glycemic control early in the course of diabetes may be beneficial. Specific glycemic targets should be selected with consideration of comorbidities and risk of microvascular complications, for which evidence of benefit remains clear. 2. Multiple risk factor intervention (glucose, lipids, blood pressure, etc.) has been shown to be effective and should be offered to most patients.
3. More attention should be paid to monitoring for and avoidance of hypoglycemia in patients being treated with insulin and/or insulin secretagogues, particularly if near-normoglycemia (HbA 1c <7%) is a target.
Future Research
More research is needed on the specific cardiovascular effects of diabetes medications, particularly drugs and drug classes that are new to the market. Recent US Food and Drug Administration requirements for defined cardiovascular trials, while criticized by some as an impediment to the drug development process, have the potential to provide critically needed information. At this time, it seems unlikely that additional large cohort studies addressing the issue of glycemic control and CVD will be undertaken. However, existing cohorts and ongoing studies can be leveraged to provide new insights into this important question. Given the evidence for a "legacy effect" demonstrated in the UKPDS and DCCT/EDIC studies, it is hoped that the assembled ACCORD, ADVANCE, and VADT cohorts will be followed long term for the further development of CVD and mortality end points.
Finally, the potential CVD benefits of lifestyle change (weight loss and increased physical activity) have received comparatively little attention. Results of the ongoing Look AHEAD (Action for Health in Diabetes) trial, which is testing the efficacy of an intensive lifestyle program in patients with established diabetes, will provide welcome insight [71] . In addition, information about the vascular benefits of intervention (lifestyle change or metformin) early in the course of dysglycemia will be forthcoming from the Diabetes Prevention Program Outcome Study, conducted in a cohort with prediabetes [72] . In the meantime, glycemic targets for the prevention of CVD should be determined based on each patient's unique risk profile and appreciation for the complex pathophysiology of vascular outcomes in type 2 diabetes.
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